Elevance Health, Inc. (ELV)
(Delayed Data from NYSE)
$274.66 USD
-8.42 (-2.97%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $274.50 -0.16 (-0.06%) 7:58 PM ET
5-Strong Sell of 5 5
A Value F Growth F Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ELV 274.66 -8.42(-2.97%)
Will ELV be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ELV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELV
Cigna to Report Q2 Earnings: Can Evernorth Offset Healthcare Weakness?
Can Humana Beat Q2 Earnings Estimates on Insurance Unit Strength?
ELV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can Optum Support UnitedHealth's Profit Amid Industry Headwinds?
Medical Expenses Erode Centene's Bottom Line in Rare Q2 Earnings Miss
Company News for Jul 18, 2025
Other News for ELV
Thermo Fisher Scientific Inc Sees Significant Reduction in Eaton Vance Worldwide Health ...
UnitedHealth sets 2025 outlook below consensus amid rising medical costs
UnitedHealth stumbles on weak profit outlook, drags peers lower
UnitedHealth stumbles as annual profit outlook disappoints
UnitedHealth Stock Is A Strong Buy Amid Unfavorable Medical Trends (Upgrade)